1BALFOUR JA, LAMB HM. Moxifloxacin:a review of its clinical potential in management of community-acquired respiratory tract infection[J]. Drugs, 2000, 59(1):115-139.
2HOEFFKEN G, MEYER HP. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithmmycin in the treatment of community-acquired pneumonia[J]. Respir Med, 2001,95(7) :553-564.
3American Thoracic Society. Guidelines for the management of adults with community acquired pneumonia [ J ] . Am J Respir Crit Care Med, 2001, 163(3) :1730-1754.
4NIEDERMAN MS. Guidelines for the management of community-acquired pneumonia[ J]. Med Clin North Am, 2001, 85 (5) : 1493-1509.
5MAN I, MURPHY J, FERGUSON J. Fluoroquinolone phototoxicity :a comparison of moxifloxaein and lomefloxaein in normal volunteers [ J ]. Antimierobial Chemotherapy, 1999,43 ( Suppl B) :77-82.
6陈灏珠.实用内科学（第11版）[M].北京:人民卫生出版社,2001.1785.
7Aamerican Thoracic Society. Guidelines for the management of adults with community acquired pneumonia[J]. Am J Respir Crit Care Med,2001,163:1730.
8European Respiratory Society. Guidelines for management of adult community-acquired lower respiratory tract infections[J]. Eur Respir J,1998,11(4):986.
9Blondeau JM, Laskowski R, Bjarnason J, et al. Comparative in vitro activity of gatifloxacin, grepagloxacin, Ievofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms [J]. Int I Antimicrob Agents ,2000,14:450.
10Urueta J, Ariza J, de Brito A, et al. Safety and efficacy of moxifloxacin vs levofloxacin in the treatment of AECB[J]. Clin Microbiol Infect ,2001,7(Suppl) 1:168.
